NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study.

Kiknavelidze, Koba; Shavdia, Mikheil; Chikhladze, Nana; Abshilava, Lia; Messina, Marinella; Mautner, Gisela; Kelly, Graham

Kiknavelidze, Koba; Shavdia, Mikheil; Chikhladze, Nana; Abshilava, Lia; Messina, Marinella; Mautner, Gisela; Kelly, Graham.

Afiliación

Kiknavelidze K; Oncology Unit, Z Tskhakaia West Georgia National Center of Interventional Medicine, Kutaisi, Georgia.
Shavdia M; JSC Neo Medi, Tbilisi, Georgia.
Chikhladze N; First Clinic of Tbilisi State Medical University, Tbilisi, Georgia.
Abshilava L; Medulla-Chemotherapy and Immunotherapy Center, Tbilisi, Georgia.
Messina M; Noxopharm Limited, Gordon, New South Wales, Australia.
Mautner G; Noxopharm Limited, Gordon, New South Wales, Australia.
Kelly G; Noxopharm Limited, Gordon, New South Wales, Australia.

Curr Ther Res Clin Exp ; 94: 100631, 2021.

Article en En | MEDLINE | ID: mdl-34306271

Palabras clave

NOX66; cytotoxic chemotherapy; drug resistance; idronoxil; immunomodulation; oncology

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Observational_studies Idioma: En Revista: Curr Ther Res Clin Exp Año: 2021 Tipo del documento: Article País de afiliación: Georgia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google